Attenuated recombinant mycobacteria useful as immunogens or as vaccine components
AssigneeInstitut Pasteur
InventorsBridgitte Gicquel, Christophe Guilhot, Mary Jackson
Life of this patent
Estimating the term…
Abstract
This invention provides recombinant mycobacterium strains of pathogenic origin that have been attenuated by the inactivation of a gene coding for a metabolic protein, specifically a gene coding for a protein necessary for the biosynthesis of a purine or a pyrimidine base, and more precisely, the purC gene that codes for an enzyme of the metabolic pathway of purine biosynthesis. The recombinant mycobacterium of this invention have a reduced capacity to propagate in a mammalian host, but remain viable in the host for a period of time sufficient to induce an protective immune response against the natural pathogenic mycobacterium counterpart.
Claims3
The recombinant mycobacterium strain MYC 1551 (C.N.C.M. No. I-1871).
The recombinant mycobacterium strain MYC 1552 (C.N.C.M. No. I-1872).
A recombinant mycobacterium strain of pathogenic origin capable of replicating in a macrophage of a host, said strain containing in its chromosome or on a plasmid a counterpart to a gene in the wild type mycobacterium coding for a protein necessary for the biosynthesis of a purine or a pyrimidine base, wherein said counterpart gene in the recombinant mycobacterium has been inactivated by at least one point mutation or by addition, deletion, or substitution of one or more base pairs, wherein said mycobacterium strain is selected from the group consisting of M. Bovis-BCG, M. tuberculosis, and M. smegmatis, and said inactivated gene is a purC or purL gene.
Dependencies are inferred from the claim text.